Lexaria Bioscience Corp.
LEXX
$4.76
-$1.11-18.84%
NASDAQ
| 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 47.45% | 46.56% | 41.01% | -23.39% | -112.67% |
| Total Depreciation and Amortization | -29.47% | 189.13% | -39.50% | 15.32% | 74.31% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -81.85% | -55.29% | -16.10% | 270.17% | 22.44% |
| Change in Net Operating Assets | 168.73% | -178.25% | 376.69% | -286.04% | -550.98% |
| Cash from Operations | 54.38% | -44.46% | 63.90% | -39.69% | -183.07% |
| Capital Expenditure | -- | -- | -- | 100.00% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -39.69% | 53.05% | 61.36% | -493.61% | 11.82% |
| Cash from Investing | -39.69% | -93.19% | 86.51% | -126.87% | 11.82% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | 25,917.95% | -20.05% | -- | -66.51% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.00% | 25,917.95% | -20.05% | -- | -66.51% |
| Foreign Exchange rate Adjustments | -75.81% | 121.62% | -78.13% | 409.52% | 3,200.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 11.94% | 152.63% | 57.06% | -42.38% | -150.01% |